We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 07, 2021

Long-Term Outcomes With Advanced Melanoma and Initial Stable Disease With Pembrolizumab

European Journal of Cancer


Additional Info

European Journal of Cancer
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006
Eur. J. Cancer 2021 Nov 01;157(xx)391-402, O Hamid, C Robert, A Daud, MS Carlino, TC Mitchell, P Hersey, J Schachter, GV Long, FS Hodi, JD Wolchok, A Arance, JJ Grob, AM Joshua, JS Weber, L Mortier, E Jensen, SJ Diede, BH Moreno, A Ribas

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading